QIAGEN partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V. (Euronext: CURE), to develop innovative bioinformatics and assay solutions to accelerate research targeting the growing global health challenges posed by antibiotic-resistant bacteria.

Article: Finanznachrichten

Article: Qiagen